Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:25:32 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		0.00%	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.3K 81.78K 76.56K 144K 9.56M 144K 970K 376K 4.7M 380K 372K 16.33M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.88M 9.15M 8.57M 16.07M 1.07B 16.16M 109M 42.08M 526M 42.54M 41.63M 1.83B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	88.85%	Yield 2022 *	-	Yield 2023	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		11,904.01
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-02-28	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
24-01-11	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
24-01-11	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	0.00%	-	-100.00%	136
ARGENX SE	+1.44%	-1.25%	+64.25%	+114.23%	55.19B
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+57.38%	+48.98%	45.75B
BIONTECH SE	-1.44%	+0.39%	-14.68%	-17.33%	22.98B
INSMED INCORPORATED	-2.69%	-2.10%	-6.70%	+374.02%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	-0.84%	+27.88%	-20.46%	16.26B
GENMAB A/S	+0.58%	+1.08%	+18.85%	-37.32%	15.42B
EXELIXIS, INC.	-1.01%	-2.30%	+28.59%	+174.08%	13.05B
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+125.78%	+252.19%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+0.14%	+29.05%	-	12.37B
Average	+991.27%	+2.01%	+36.71%	+87.60%	21.42B
Weighted average by Cap.	+1.63%	+1.48%	+40.78%	+101.14%

	2022	2023
Net sales	-	2.2 1.92 1.78 1.67 3.12 207.87 3.14 21.1 8.18 102.32 8.27 8.09 355.27
Net income	-73.53M -64.11M -59.38M -55.59M -104M -6.94B -105M -704M -273M -3.42B -276M -270M -11.86B	-37.88M -33.03M -30.59M -28.64M -53.71M -3.57B -54.03M -363M -141M -1.76B -142M -139M -6.11B
Net Debt	4.59M 4M 3.71M 3.47M 6.51M 433M 6.55M 43.96M 17.04M 213M 17.23M 16.86M 740M	11.23M 9.79M 9.07M 8.49M 15.92M 1.06B 16.02M 108M 41.7M 522M 42.16M 41.26M 1.81B